 Gritstone bio results from the phase 12 study, using SLATE vaccines in treating patients with KRAS mutant MSS-CRC and NSCLC, were positive with a 39 molecular response observed. Molecular response achieved in KRAS mutant NSCLC patients led to a doubling of overall survival; previous checkpoint inhibitor literature and another study using GRANITE proved this correlation. 